RNS31 Jan 2017 13:01
Hardman Research: ThioBridge deal highlights undervaluation
ThioBridge deal highlights undervaluation: Abzena is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a fee-for-service offering with the additional opportunity to embed its technology - 'Abzena Inside' - into commercial products, on which it will derive a long-term royalty stream. Abzena has signed a licensing deal with a US biopharmaceutical company for the use of its ThioBridge technology. This deal has a potential value exceeding $300m and has significantly boosted market confidence in the company.
Buy big.